Summit Therapeutics Inc. (SMMT)

Market Cap	18.31B
Revenue (ttm)	n/a
Net Income (ttm)	-240.76M
Shares Out	742.67M
EPS (ttm)	-0.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,879,129
Open	24.52
Previous Close	24.29
Day's Range	24.00 - 25.74
52-Week Range	2.10 - 36.91
Beta	-0.95
Analysts	Strong Buy
Price Target	37.00 (+50.1%)
Earnings Date	May 1, 2025

About SMMT

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 159
• Stock Exchange: NASDAQ
• Ticker Symbol: SMMT
• Website: https://www.smmttx.com

Analyst Forecast

According to 11 analysts, the average rating for SMMT stock is "Strong Buy." The 12-month stock price forecast is $37.0, which is an increase of 50.10% from the latest price.

Price Target

$37.0

(50.10% upside)

Analyst Consensus: Strong Buy